𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma

✍ Scribed by Maria L. Delioukina; Diane Prager; Mandy Parson; J. Randolph Hecht; Peter Rosen; Lee S. Rosen

Publisher
John Wiley and Sons
Year
2002
Tongue
English
Weight
71 KB
Volume
94
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A multicenter, Phase II trial of weekly
A multicenter, Phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma
✍ Mace L. Rothenberg; John V. Cox; Russell F. DeVore; John D. Hainsworth; Richard πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 110 KB πŸ‘ 2 views

## Background: This multicenter, phase ii trial was performed to evaluate the antitumor activity and toxicity of irinotecan (cpt-11) in patients with metastatic colorectal carcinoma that had recurred or progressed after 5-fluorouracil (5-fu)-based chemotherapy. ## Methods: Cpt-11 was given as a 9

A Phase II study of irinotecan in patien
A Phase II study of irinotecan in patients with advanced renal cell carcinoma
✍ Karim Fizazi; FrΓ©dΓ©ric Rolland; Christine Chevreau; Jean-Pierre Droz; Dominique πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 71 KB πŸ‘ 2 views

## Abstract ## BACKGROUND Patients with disseminated renal cell carcinoma (RCC) have a poor outcome, and the disease is considered highly resistant to chemotherapy. Irinotecan is an active drug in the treatment of a number of neoplastic diseases and is not concerned with the multidrug‐resistance p

A phase II trial of gemcitabine in patie
A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma
✍ Charles S. Fuchs; Jeffrey W. Clark; David P. Ryan; Mathew H. Kulke; Haesook Kim; πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 74 KB πŸ‘ 2 views

## Abstract ## BACKGROUND There is no effective systemic therapy for patients with hepatocellular carcinoma. A recent trial reported a moderate antitumor activity for gemcitabine among Asian patients with advanced hepatocellular carcinoma. This led to our examination of the efficacy and tolerabili